CSTD002-NK

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCSTD002-NK
Drug Alias NameK-NK002CSTD-002CSTD002-NK
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKiadis PharmaThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKiadis Pharma
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A